The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
 
Geraldine Helen O'Sullivan Coyne
No Relationships to Disclose
 
Andrea M. Gross
No Relationships to Disclose
 
Eva Dombi
No Relationships to Disclose
 
Cecilia Tibery
No Relationships to Disclose
 
Amanda Carbonell
No Relationships to Disclose
 
Naoko Takebe
No Relationships to Disclose
 
Joanne Derdak
No Relationships to Disclose
 
Dominique Pichard
No Relationships to Disclose
 
Apurva K. Srivastava
No Relationships to Disclose
 
William Herrick
No Relationships to Disclose
 
Ralph E. Parchment
Employment - Leidos Biomedical Research
Stock and Other Ownership Interests - SciTech Development LLC
Patents, Royalties, Other Intellectual Property - Cambridge University Press for The Biological Basis of Cancer; Named Inventor on US Patent 9,644,037; Named inventor on US Patent US8709379 B2
Travel, Accommodations, Expenses - Sanofi/Aventis
 
Staci Martin
No Relationships to Disclose
 
Pamela Wolters
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Patricia Whitcomb
No Relationships to Disclose
 
Lawrence Rubinstein
No Relationships to Disclose
 
James H. Doroshow
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
Brigitte C. Widemann
No Relationships to Disclose